Search Result

Results for "

L1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Akt (2) AMPK (5) Apoptosis (15) Aryl Hydrocarbon Receptor (1) Autophagy (2) Bacterial (5) Bcl-2 Family (1) Beta-lactamase (2) Beta-secretase (2) Biochemical Assay Reagents (1) c-Myc (2) Cannabinoid Receptor (1) Caspase (2) CaSR (1) CDK (1) Cholinesterase (ChE) (2) COX (1) Cytochrome P450 (4) Deubiquitinase (5) DGK (1) DNA Stain (1) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Eukaryotic Initiation Factor (eIF) (1) Fatty Acid Synthase (FASN) (1) Free Fatty Acid Receptor (1) Fungal (3) Glucosidase (1) GPR109A (1) HBV (1) HDAC (4) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (2) HPV (1) HSP (3) IFNAR (1) IKK (1) Integrin (1) Interleukin Related (1) LAG-3 (2) Ligands for Target Protein for PROTAC (2) MAP4K (1) MMP (1) MNK (1) Monoamine Oxidase (3) NF-κB (1) p38 MAPK (1) PD-1/PD-L1 (136) Phosphatase (3) Phosphodiesterase (PDE) (1) PI3K (1) PKC (1) PPAR (7) PROTAC Linkers (3) PROTACs (1) Reactive Oxygen Species (3) RSV (1) Ser/Thr Protease (1) Sirtuin (1) Small Interfering RNA (siRNA) (59) Src (1) STAT (4) STING (1) Target Protein Ligand-Linker Conjugates (2) TGF-β Receptor (1) TNF Receptor (2) Toll-like Receptor (TLR) (6) Tryptophan Hydroxylase (1) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (167) Cardiovascular Disease (1) Endocrinology (1) Infection (14) Inflammation/Immunology (46) Metabolic Disease (27) Neurological Disease (5)
Click Chemistry:	Azide (1)

280

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

102

Recombinant Proteins

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124379

TPCK 1 Publications Verification L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK	Ser/Thr Protease HPV	Inflammation/Immunology Cancer
TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is a potent serine protease inhibitor that reacts with the retinoblastoma protein (RB)-binding core of HPV-18 E7 protein and abolish its RB-binding capability. TPCK is able to modify E7 protein in live keratinocytes following its addition to the culture medium ^[1].

HY-150202

L1-PEG2-TATE

Others Others

L1-PEG2-TATE is a nonadentate ligand. L1-PEG2-TATE can be used for the research of imaging ^[1].

L1-PEG2-TATE	Others	Others
L1-PEG2-TATE is a nonadentate ligand. L1-PEG2-TATE can be used for the research of imaging ^[1].

HY-W012846A

L-Threitol L-1,2,3,4-Butanetetrol	Biochemical Assay Reagents	Others
L-Threitol is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-RS07481

L1CAM Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
L1CAM Human Pre-designed siRNA Set A contains three designed siRNAs for L1CAM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

L1CAM Human Pre-designed siRNA Set A L1CAM Human Pre-designed siRNA Set A

HY-RS07482

L1TD1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
L1TD1 Human Pre-designed siRNA Set A contains three designed siRNAs for L1TD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

L1TD1 Human Pre-designed siRNA Set A L1TD1 Human Pre-designed siRNA Set A

HY-N7825

Gomisin L1

Others Cancer

Gomisin L1 is a lignan, shows inhibitory effect on cell viability of A2780 and Ishikawa cells, with IC₅₀s of 39.06 μM and 74.16 μM, respectively ^[1].

Gomisin L1	Others	Cancer
Gomisin L1 is a lignan, shows inhibitory effect on cell viability of A2780 and Ishikawa cells, with IC₅₀s of 39.06 μM and 74.16 μM, respectively ^[1].

HY-149830

PD-L1-IN-2	PD-1/PD-L1	Cancer
PD-L1-IN-2 is a potential tumor immunological agent by inhibiting *PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1*-IN-2 is used for colorectal cancer research ^[1].

HY-155101

PD-L1-IN-3	PD-1/PD-L1	Cancer
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC₅₀ value and EC₅₀ value is 4.97nM and 2.70 μM for inhibit *PD-L1* and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research ^[1].

HY-139781

PD-L1-IN-1	PD-1/PD-L1	Cancer
PD-L1-IN-1 is a potent *PD-L1* inhibitor with an IC₅₀ of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells ^[1].

HY-162356

PD-L1-IN-4	PD-1/PD-L1	Cancer
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer ^[1].

HY-P2564

Human PD-L1 inhibitor III

PD-1/PD-L1 Inflammation/Immunology Cancer

Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

Human PD-L1 inhibitor III	PD-1/PD-L1	Inflammation/Immunology Cancer
Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

HY-152240

PD-1/PD-L1-IN-29	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity ^[1].

HY-162357

PD-L1-IN-5

PD-1/PD-L1 Cancer

PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor, with the IC₅₀ value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo ^[1].

PD-L1-IN-5	PD-1/PD-L1	Cancer
PD-L1-IN-5 (X22) is an orally active *PD-L1* inhibitor, with the IC₅₀ value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo ^[1].

HY-157811

PD-1/PD-L1-IN-40	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-40 (Compound EP16) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-40 inhibits the generation of exosomal PD-L1 with IC₅₀ = 0.108 μM. PD-1/PD-L1-IN-40 can serve as a leading compound for exosomal PD-L1 abrogation. PD-1/PD-L1-IN-40 can be used for the research of cancer ^[1].

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-162399

PD-L1-IN-6	PD-1/PD-L1 STAT	Inflammation/Immunology
PD-L1-IN-6 (Compound 16) is an orally active inhibitor for *PD-L1* expression in neutrophil by targeting STAT3 with K_D of 90.5 nmol/L. PD-L1-IN-6 promotes neutrophil-mediated antifungal immunoresponse ^[1].

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-144258

PD-1/PD-L1-IN-14	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 ^[1].

HY-P2470

Human PD-L1 inhibitor II

PD-1/PD-L1 Cancer

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity ^[1].

Human PD-L1 inhibitor II	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor II is a potent *PD-L1* inhibitor with anti-cancer activity ^[1].

HY-P2474

Human PD-L1 inhibitor I	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a *hPD-1* peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 ^[1].

HY-145774

PD-1/PD-L1-IN-23	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1*/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice ^[1].

HY-155959

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity ^[1].

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-144447

PD-1/PD-L1-IN-17	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-17 (Compound P20) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 26.8 nM. PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-17 has the potential for the research of cancer diseases ^[1].

HY-145770

PD-1/PD-L1-IN-19	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-19 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-19 blocks PD-1/PD-L1 with the IC₅₀ of 62.3 nM. PD-1/PD-L1-IN-19 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-163307

PD-1/PD-L1-IN-39	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-39 (X 14) is an orally active *PD-1/PD-L1* inhibitor with a IC₅₀ value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with K_D values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity ^[1].

HY-130625

PD-1/PD-L1-IN 6	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN 6 (compound A13) is a potent *PD-1/PD-L1* interaction inhibitor, with an IC₅₀ of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model ^[1].

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a K_d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

HY-108730A

Avelumab (anti-PD-L1) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (anti-PD-L1) is a fully human *IgG1* anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity ^[1].

HY-P5276

Human membrane-bound PD-L1 polypeptide

PD-1/PD-L1 Cancer

Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production ^[1].

Human membrane-bound PD-L1 polypeptide	PD-1/PD-L1	Cancer
Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce *PD-L1* antibody production ^[1].

HY-145772

PD-1/PD-L1-IN-21	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-21 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-21 blocks PD-1/PD-L1 with the IC₅₀ of 4.99 μM. PD-1/PD-L1-IN-21 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-145773

PD-1/PD-L1-IN-22	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-22 (Example 2) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-22 blocks PD-1/PD-L1 with the IC₅₀ of 0.732 μM. PD-1/PD-L1-IN-22 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-145768

PD-1/PD-L1-IN-18	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-18 (Compound L31) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-18 blocks PD-1/PD-L1 with the IC₅₀ of 1.054 μM. Antitumor Activity ^[1].

HY-131183

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a *PD-1/PD-L1* PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner ^[1].

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-143305

PD-1/PD-L1-IN-25	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of *PD-1/PD-L1* interaction with an IC₅₀ value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer ^[1].

HY-N12537

PD-1/PD-L1-IN-38	PD-1/PD-L1	Cancer
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity ^[1].

HY-163041

PD-1/PD-L1-IN-36	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-36 (Compound 2k) is a *PD-1/PD-L1* complex inhibitor (IC₅₀: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy ^[1].

HY-160585

PD-L1/PD-1-IN-1	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1/PD-1-IN-1 (compound 8j) is a potent inhibitor of *PD-L1/PD* interaction, with IC₅₀ ＜ 1 nM. PD-L1/PD-1-IN-1 plays an important role in anti-tumor research ^[1].

HY-146740

PD-1/PD-L1-IN-27	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-27 is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8 ⁺ T cells and reduces T cell exhaustion ^[1].

HY-144649

PD-1/PD-L1-IN-24	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-24 is a highly potent *PD-1/PD-L1* inhibitor with IC₅₀ value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs ^[1].

HY-155740

PD-1/PD-L1-IN-32	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-32 (compound A56) is a potent PD-1/PD-L1 inhibitor (IC₅₀=2.4 nM), with anticancer activity. PD-1/PD-L1-IN-32 significantly inhibits tumor growth in hPD-L1 MC38 humanized mouse model, without obvious toxicity against mouse normal ability ^[1].

HY-144442

PD-1/PD-L1-IN-15	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-15 (Compound M17) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 60.1 nM. PD-1/PD-L1-IN-15 has the potential for the research of tumor immunoresearch ^[1].

HY-144443

PD-1/PD-L1-IN-16	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-16 (Compound M23) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 53.2 nM. PD-1/PD-L1-IN-16 has the potential for the research of tumor immunoresearch ^[1].

HY-131347

PD-1/PD-L1-IN-NP19	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-NP19 is a *PD-1/PD-L1* inhibitor, with an IC₅₀ of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects ^[1].

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy ^[1].

HY-162343

PD-1/PD-L1-IN-41

PD-1/PD-L1 Inflammation/Immunology Cancer

PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and PD-1 inhibitor with IC₅₀ value of 10.2 nM ^[1].

HY-132192

PD-1/PD-L1-IN-9	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

HY-144746

PD-1/PD-L1-IN-26	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases ^[1].

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

486 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 486 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L079

Anti-Blood Cancer Compound Library

2676 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2676 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L007

Immunology/Inflammation Compound Library

5006 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 5006 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

HY-L109

Protein-protein Interaction Inhibitor Library

576 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 576 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-P2470

Human PD-L1 inhibitor II

PD-1/PD-L1 Cancer

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity ^[1].

HY-P2474

Human PD-L1 inhibitor I	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a *hPD-1* peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 ^[1].

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P2564

Human PD-L1 inhibitor III

PD-1/PD-L1 Inflammation/Immunology Cancer

Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a K_d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

HY-P5276

Human membrane-bound PD-L1 polypeptide

PD-1/PD-L1 Cancer

Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production ^[1].

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy ^[1].

HY-P3440

WL12	PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression ^[1].

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-125357

Ternatin	Peptides	Metabolic Disease
Ternatin (compound 2) is a cyclic heptapeptides that can be isolated from mushroom Coliorus versicolor. Ternatin inhibits fat-accumulation with an IC₅₀ of 0.027 μM in 3T3-L1 adipocytes ^[1].

HY-P3342

[D-Leu-4]-OB3	PD-1/PD-L1 Apoptosis	Inflammation/Immunology
[D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1* expression.* [D-Leu-4]-OB3 stimulates expression of pro-apoptotic genes ^[1].

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P10091

CD24/Siglec-10 blocking peptide, CSBP	PD-1/PD-L1	Cancer
CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell ^[1].

HY-12557

γ-Glutamylvaline	CaSR Wnt TNF Receptor	Inflammation/Immunology
γ-Glutamylvaline is an activator of CaSR with anti-inflammatory activity. γ-Glutamylvaline inhibits TNF-α-induced proinflammatory cytokine production and increases Wnt5a expression. γ-Glutamylvaline activates calcium-sensing receptor pathways in adipocytes of 3T3-L1 mice and prevents low-grade chronic inflammation ^[1].

HY-P1812

AUNP-12 NP-12	PD-1/PD-L1	Cancer
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P1812A

AUNP-12 TFA NP-12 TFA	PD-1/PD-L1	Cancer
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

Cat. No.	Product Name	Target	Research Area

HY-108730A

Avelumab (anti-PD-L1) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (anti-PD-L1) is a fully human *IgG1* anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity ^[1].

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)

PD-1/PD-L1 Inflammation/Immunology

Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse PD-L1 IgG2b antibody inhibitor derived from host rat.

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-P990173

Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)	Inhibitory Antibodies	Others
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human PD-L1.

HY-P990114

Anti-Canine PD-L1/B7-H1 Antibody (JC071)	Inhibitory Antibodies	Others
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to canine PD-L1/B7-H1.

HY-108730

Avelumab 5+ Cited Publications Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

HY-P99145A

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2™-CP168)	Inhibitory Antibodies	Others
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2?-CP168) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.

HY-P990171

Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2™-CP154)	Inhibitory Antibodies	Others
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2?-CP154) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.

HY-P990172

Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2™-CP001)	Inhibitory Antibodies	Others
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2?-CP001) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- *PD-L1* antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25 nM. Envafolimab has the potential for the research of solid tumors ^[1] .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells ^[1].

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to *PD-L1*. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity ^[1].

HY-P9919

Durvalumab 5 Publications Verification MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody ^[1]. Durvalumab (MEDI4736) completely blocks the binding of *PD-L1* to both *PD-1* and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a *humanized anti-PD-L1 antibody* (IgG1κ type). Tagitanlimab selectively blocks the interaction of *PD-L1* and *PD-1*. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) ^[1] .

HY-P99422

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal *PD-L1* (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) ^[1] .

HY-P99723

Manelimab

BCD-135
PD-1/PD-L1 Cancer

Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) ^[1].
HY-P99799

Pacmilimab

CX-072
PD-1/PD-L1 Cancer

Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity ^[1].

HY-P99419

Acasunlimab GEN1046	PD-1/PD-L1	Cancer
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting *PD-L1* and *4-1BB*. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer ^[1] .

HY-P99944

SHR-1701

Retlirafusp alfa
PD-1/PD-L1 TGF-β Receptor Cancer

SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research ^[1].
HY-P990035

Benmelstobart

PD-1/PD-L1 Cancer

Benmelstobart is an IgG1κ antibody targeting PD-L1/CD274, derived from mice ^[1].

HY-P9904

Atezolizumab Maximum Cited Publications 19 Publications Verification MPDL3280A	PD-1/PD-L1 Apoptosis Autophagy	Cancer
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-P9996

Reozalimab

LY3434172
PD-1/PD-L1 Cancer

Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research ^[1] .

HY-P99475

Betifisolimab MSB-2311	PD-1/PD-L1	Cancer
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research ^[1].

HY-P99785

Opucolimab HLX20	PD-1/PD-L1	Cancer
Opucolimab is an *anti-PD-L1* recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors ^[1].

HY-P99100

Visugromab

CTL-002
PD-1/PD-L1 Cancer

Visugromab is aGDF-15 neutralizing IgG4 mAb. Visugromab exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors ^[1].

HY-P9971

Camrelizumab 1 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀* of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al ^[1] .

HY-P9972

Spartalizumab PDR001	PD-1/PD-L1	Cancer
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds *PD-1* with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) ^[1].

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research ^[1].

HY-P9986

Tiragolumab	Inhibitory Antibodies	Inflammation/Immunology Cancer
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC) ^[1] .

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with *PD-L1* and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo ^[1].

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) ^[1] .

HY-P99639

Geptanolimab APL-501; CBT-501; GB-226	PD-1/PD-L1	Cancer
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer ^[1].

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively ^[1].

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma ^[1] .

HY-P99203

Cemiplimab	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research ^[1] .

HY-P9902A

Pembrolizumab (anti-PD-1) 2 Publications Verification	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1*. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 ^[1] .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to *PD-1*, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer ^[1].

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against *PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF*-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment ^[1].

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized *VEGFR-1* extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human *PD-L1* heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor ^[1].

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma ^[1] .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with *PD-L1* and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo ^[1].

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific *PD-1/LAG-3* dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity ^[1] .

Species:	Human (57) Virus (2) Rhesus Macaque (2) Mouse (26) Rat (6) Cynomolgus (5) Canine (4)
Tag:	His (75) SUMO (2) Tag Free (7) Avi (3) Myc (3) GST (2) MBP (1) Fc (22) Flag (1)
Source:	HEK293 (65) E. coli Cell-free (1) CHO (1) Sf9 insect cells (8) P. pastoris (2) E. coli (25)

Cat. No.	Compare	Product Name	Species	Source

HY-P74791

	L1CAM Protein, Human (HEK293, His) Neural cell adhesion molecule L1; NCAM-L1; CD171; L1CAM; CAML1; MIC5	Human	HEK293
	The L1CAM protein is a neural cell adhesion molecule that plays a critical role in cell adhesion dynamics and initiation of tyrosine kinase receptor transmembrane signaling. Its importance spans brain development, affecting processes such as neuronal migration, axonal growth, fasciculations, and synaptogenesis. L1CAM Protein, Human (HEK293, His) is the recombinant human-derived L1CAM protein, expressed by HEK293 , with C-His labeled tag. The total length of L1CAM Protein, Human (HEK293, His) is 1101 a.a., with molecular weight of 160-200 kDa.

HY-P700417

	L1CAM Protein, Human (HEK293, C-His) L1 cell adhesion molecule; antigen identified by monoclonal R1 , HSAS, HSAS1, MASA, MIC5, S10, SPG1; neural cell adhesion molecule L1; CD171; antigen identified by monoclonal R1; S10; HSAS; MASA; MIC5; SPG1; CAML1; HSAS1; N-CAML1; NCAM-L1; N-CAM-L1	Human	HEK293
	The L1CAM protein is a neural cell adhesion molecule that plays a critical role in cell adhesion dynamics and initiation of tyrosine kinase receptor transmembrane signaling. Its importance spans brain development, affecting processes such as neuronal migration, axonal growth, fasciculations, and synaptogenesis. L1CAM Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived L1CAM protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of L1CAM Protein, Human (HEK293, N-His, C-Myc) is 1101 a.a., with molecular weight of 150-200 kDa.

HY-P77732

	L1CAM Protein, Mouse (HEK293, His) N-CAM-L1; NCAM-L1; CD171; L1CAM; CAML1; MIC5; CALL; CHL1; CHL-1; FLJ44930; L1CAM-2; MGC132578; HSAS; HSAS1; MASA; S10; SPG1	Mouse	HEK293
	The L1CAM protein is a neural cell adhesion molecule that plays a key role in cell adhesion dynamics and transmembrane signaling during brain development. It contributes to neuronal migration, axonal growth, fasciculation, and synaptogenesis. L1CAM Protein, Mouse (HEK293, His) is the recombinant mouse-derived L1CAM protein, expressed by HEK293 , with C-His labeled tag. The total length of L1CAM Protein, Mouse (HEK293, His) is 1104 a.a., with molecular weight of 160-180 kDa.

HY-P73468

	VCAM-1/CD106 Protein, Human (HEK293, Fc) Vascular Cell Adhesion Protein 1; VCAM-1; INCAM-100; CD106; L1CAM	Human	HEK293
	VCAM-1/CD106 proteins expressed on endothelial cells critically regulate leukocyte adhesion through integrin interactions, initiating calcium channel activation and RAC1-mediated transendothelial migration during inflammation. VCAM-1/CD106 Protein, Human (HEK293, Fc) is the recombinant human-derived VCAM-1/CD106 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VCAM-1/CD106 Protein, Human (HEK293, Fc) is 673 a.a., with molecular weight of 110-150 kDa.

HY-P73470

VCAM-1/CD106 Protein, Mouse (HEK293, His)

Vascular Cell Adhesion Protein 1; VCAM-1; INCAM-100; CD106; L1CAM
Mouse HEK293
HY-P73469

VCAM-1/CD106 Protein, Mouse (HEK293, His-Fc)

Vascular Cell Adhesion Protein 1; VCAM-1; INCAM-100; CD106; L1CAM
Mouse HEK293

HY-P78948

	VCAM-1/CD106 Protein, Human (Biotinylated, HEK293, hFc) Vascular Cell Adhesion Protein 1; V-CAM 1; VCAM-1; INCAM-100; CD106; VCAM1; L1CAM	Human	HEK293
	VCAM-1/CD106 proteins expressed on endothelial cells critically regulate leukocyte adhesion through integrin interactions, initiating calcium channel activation and RAC1-mediated transendothelial migration during inflammation. VCAM-1/CD106 Protein, Human (Biotinylated, HEK293, hFc) is the recombinant human-derived VCAM-1/CD106 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VCAM-1/CD106 Protein, Human (Biotinylated, HEK293, hFc) is 673 a.a., with molecular weight of ~101 kDa.

HY-P7777

	VCAM-1/CD106 Protein, Human (HEK293, His) rHuCD106, His; Vascular Cell Adhesion Protein 1; V-CAM 1; VCAM-1; INCAM-100; CD106; VCAM1; L1CAM	Human	HEK293
	CD106 Protein, Human (HEK293, His) is a cytokine-inducible cell surface protein capable of mediating adhesion.

HY-P7754

	Cathepsin L1 Protein, Human (HEK293, His) rHuCathepsin L1, His; Cathepsin L1; Major Excreted Protein; MEP; CTSL1; CTSL	Human	HEK293
	Cathepsin L1 Protein, Human (HEK293, His) is a major cysteine protease that plays a major role in intracellular protein catabolism.

HY-P7754A

	Cathepsin L1 Protein, Human (HEK293, C-His) rHuCathepsin L1, His; Cathepsin L1; Major Excreted Protein; MEP; CTSL1; CTSL	Human	HEK293
	Cathepsin L1 protein is a thiol protease that plays a key role in lysosomal protein degradation, affecting cellular functions such as turnover, antigen processing, and bone remodeling. It dissolves cross-linked TG/thyroglobulin, releasing the thyroid hormone thyroxine (T4) in the thyroid follicular cavity. Cathepsin L1 Protein, Human (HEK293, C-His) is the recombinant human-derived Cathepsin L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Cathepsin L1 Protein, Human (HEK293, C-His) is 316 a.a., with molecular weight of ~32.8 kDa.

HY-P7753

	Cathepsin L1 Protein, Mouse (HEK293, His) rMuCathepsin L, His; Cathepsin L1; Major excreted protein; p39 cysteine proteinase; CTSL1	Mouse	HEK293
	Cathepsin L Protein, Mouse (HEK293, His) is a lysosomal acid cysteine protease, which is associated with tumor occurrence, development, and metastasis.

HY-P71096

	UCHL1 Protein, Human (His) Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1; UCH-L1; Neuron Cytoplasmic Protein 9.5; PGP 9.5; PGP9.5; Ubiquitin Thioesterase L1; UCHL1	Human	E. coli
	The UCHL1 protein is a multifunctional deubiquitinase that regulates a variety of cellular processes. It maintains synaptic and cardiac function, modulates inflammatory responses, and influences osteoclastogenesis. UCHL1 Protein, Human (His) is the recombinant human-derived UCHL1 protein, expressed by E. coli , with C-6*His labeled tag. The total length of UCHL1 Protein, Human (His) is 223 a.a., with molecular weight of ~26.0 kDa.

HY-P73466

	UCHL1 Protein, Mouse (His) Ubiquitin carboxyl-terminal hydrolase isozyme L1; UCH-L1; UchL1; PGP9.5	Mouse	E. coli
	UCHL1 Protein, a ubiquitin carboxyl-terminal hydrolase, plays a crucial role in protein degradation and regulation of cellular processes. It is involved in maintaining neuronal integrity and has been linked to neurodegenerative diseases. UCHL1 Protein's potential as a biomarker and therapeutic target in neurodegenerative disorders makes it a subject of intense research in the field of neuroscience. UCHL1 Protein, Mouse (His) is the recombinant mouse-derived UCHL1 protein, expressed by E. coli , with N-His labeled tag. The total length of UCHL1 Protein, Mouse (His) is 222 a.a., with molecular weight of ~29 kDa.

HY-P74483

	UCHL1 Protein, Rat (His) Ubiquitin carboxyl-terminal hydrolase isozyme L1; UCH-L1; UchL1; PGP9.5	Rat	E. coli
	The UCHL1 protein is a ubiquitin proteolytic enzyme essential for processing ubiquitin precursors and hydrolyzing ubiquitinated proteins. As a thiol protease, it specifically cleaves the C-terminal glycine of ubiquitin. UCHL1 Protein, Rat (His) is the recombinant rat-derived UCHL1 protein, expressed by E. coli , with N-10*His labeled tag. The total length of UCHL1 Protein, Rat (His) is 222 a.a., with molecular weight of ~28 kDa.

HY-P75504

	Apolipoprotein L/APOL1 Protein, Human (sf9, His) Apolipoprotein L1; Apo-L; ApoL-I; APOL1; APOL	Human	Sf9 insect cells
	Apolipoprotein L (APOL1) Protein is a member of the apolipoprotein L family. Apolipoprotein L/APOL1 Protein, Human (sf9, His) is the recombinant human-derived Apolipoprotein L/APOL1 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of Apolipoprotein L/APOL1 Protein, Human (sf9, His) is 371 a.a., with molecular weight of ~44 kDa.

HY-P75503

	Apolipoprotein A-I/APOA1 Protein, Mouse (HEK293, His) Apolipoprotein L1; Apo-L; ApoL-I; APOL1; APOL	Mouse	HEK293
	The apolipoprotein AI (APOA1) protein is key to reverse cholesterol transport, promoting tissue efflux, and serves as an important cofactor for lecithin cholesterol acyltransferase (LCAT), promoting cholesterol excretion. As a homodimer, APOA1 is a component of the sperm activating protein complex (SPAP), interacts with APOA1BP, CLU, NDRG1, SCGB3A2, NAXE and YJEFN3, exhibiting multiple molecular associations. Apolipoprotein A-I/APOA1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Apolipoprotein A-I/APOA1 protein, expressed by HEK293 , with C-His labeled tag. The total length of Apolipoprotein A-I/APOA1 Protein, Mouse (HEK293, His) is 246 a.a., with molecular weight of 27-31 kDa.

HY-P70532

	S100A9 Protein, Human Protein S100-A9; Calgranulin-B; Calprotectin L1H subunit; Leukocyte L1 complex heavy chain; MRP-14; CAGB; CFAG	Human	E. coli
	The S100A9 protein is a calcium and zinc binder that plays a critical regulatory role in inflammation and immune responses. Its diverse functions include induction of neutrophil chemotaxis, adhesion, enhanced bactericidal activity through SYK, PI3K/AKT and ERK1/2 activation, and promotion of phagocytosis. S100A9 Protein, Human is the recombinant human-derived S100A9 protein, expressed by E. coli , with tag free. The total length of S100A9 Protein, Human is 113 a.a., with molecular weight of ~14.0 kDa.

HY-P70532A

	S100A9 Protein, Human (His) Protein S100-A9; Calgranulin-B; Calprotectin L1H subunit; Leukocyte L1 complex heavy chain; MRP-14; CAGB; CFAG	Human	E. coli
	The S100A9 protein is a calcium and zinc binder that plays a critical regulatory role in inflammation and immune responses. Its diverse functions include induction of neutrophil chemotaxis, adhesion, enhanced bactericidal activity through SYK, PI3K/AKT and ERK1/2 activation, and promotion of phagocytosis. S100A9 Protein, Human (His) is the recombinant human-derived S100A9 protein, expressed by E. coli , with N-6*His labeled tag. The total length of S100A9 Protein, Human (His) is 113 a.a., with molecular weight of ~15 kDa.

HY-P70531

	S100A8 Protein, Human (C-His) Protein S100-A8; S100A8; Calgranulin-A; Cystic fibrosis antigen; Leukocyte L1 complex light chain; MRP-8	Human	E. coli
	S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (C-His) is the recombinant human-derived S100A8 protein, expressed by E. coli , with C-6*His labeled tag. The total length of S100A8 Protein, Human (C-His) is 93 a.a., with molecular weight of ~13.0 kDa.

HY-P70531A

	S100A8 Protein, Human (N-His) Protein S100-A8; S100A8; Calgranulin-A; Cystic fibrosis antigen; Leukocyte L1 complex light chain; MRP-8	Human	E. coli
	S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (N-His) is the recombinant human-derived S100A8 protein, expressed by E. coli , with N-6*His labeled tag. The total length of S100A8 Protein, Human (N-His) is 93 a.a., with molecular weight of ~12 kDa.

HY-P76586

	S100A8 Protein, Human (sf9, His) Protein S100-A8; S100A8; Calgranulin-A; Cystic fibrosis antigen; Leukocyte L1 complex light chain; MRP-8	Human	Sf9 insect cells
	S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (sf9, His) is the recombinant human-derived S100A8 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of S100A8 Protein, Human (sf9, His) is 93 a.a., with molecular weight of ~14.6 kDa.

HY-P71275

	S100A8 Protein, Rat (His) 2 Publications Verification Protein S100-A8; S100a8; Calgranulin-A; Chemotactic cytokine CP-10; Leukocyte L1 complex light chain; Migration inhibitory factor-related protein 8; MRP-8; Pro-inflammatory S100 cytokine; S100 calcium-binding protein A8; Caga; Mrp8	Rat	E. coli
	S100A8 protein functions as a danger signal in inflammation, activating innate immune cells by binding to receptors like Toll-like receptor 4 (TLR4) and receptor for advanced glycation endproducts (AGER). This triggers signaling pathways that enhance the pro-inflammatory response. S100A8 Protein, Rat (His) is the recombinant rat-derived S100A8 protein, expressed by E. coli , with C-6*His labeled tag. The total length of S100A8 Protein, Rat (His) is 89 a.a., with molecular weight of ~13.0 kDa.

HY-P700400

	CCR8 Protein-VLP, Human (HEK293, His) CCR8; chemokine (C-C motif) receptor 8; CMKBR8, CMKBRL2; C-C chemokine receptor type 8; CDw198; CKR L1; CY6; GPR CY6; TER1; CC chemokine receptor 8; chemokine receptor-like 1; chemokine (C-C) receptor 8; CC chemokine receptor CHEMR1; CC-chemokine receptor chemr1; chemokine (C-C) receptor-like 2; CCR-8; CKRL1; CMKBR8; GPRCY6; CMKBRL2; CC-CKR-8; MGC129966; MGC129973	Human	HEK293
	CCR8 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays.

HY-P700542

	CCR8 Protein, Human (Cell-Free, His) CCR8; chemokine (C-C motif) receptor 8; CMKBR8, CMKBRL2; C-C chemokine receptor type 8; CDw198; CKR L1; CY6; GPR CY6; TER1; CC chemokine receptor 8; chemokine receptor-like 1; chemokine (C-C) receptor 8; CC chemokine receptor CHEMR1; CC-chemokine receptor chemr1; chemokine (C-C) receptor-like 2; CCR-8; CKRL1; CMKBR8; GPRCY6; CMKBRL2; CC-CKR-8; MGC129966; MGC129973	Human	E. coli Cell-free
	CCR8 Protein-VLP, a receptor for CCL1/SCYA1/I-309, may regulate monocyte chemotaxis and thymic cell line apoptosis. It also acts as an alternative coreceptor with CD4 for HIV-1 infection, facilitating viral entry. The interaction with CCL1 highlights its role in mediating cellular responses to this chemokine, implying a regulatory function in immune and inflammatory processes. CCR8 Protein, Human (Cell-Free, His) is the recombinant human-derived CCR8 protein, expressed by E. coli Cell-free, with N-10*His labeled tag. The total length of CCR8 Protein, Human (Cell-Free, His) is 56 a.a., with molecular weight of 9.4 kDa.

HY-P700543

	CCR8 Protein, Human (P. pastoris, His) CCR8; chemokine (C-C motif) receptor 8; CMKBR8, CMKBRL2; C-C chemokine receptor type 8; CDw198; CKR L1; CY6; GPR CY6; TER1; CC chemokine receptor 8; chemokine receptor-like 1; chemokine (C-C) receptor 8; CC chemokine receptor CHEMR1; CC-chemokine receptor chemr1; chemokine (C-C) receptor-like 2; CCR-8; CKRL1; CMKBR8; GPRCY6; CMKBRL2; CC-CKR-8; MGC129966; MGC129973	Human	P. pastoris
	CCR8 Protein-VLP, a receptor for CCL1/SCYA1/I-309, may regulate monocyte chemotaxis and thymic cell line apoptosis. It also acts as an alternative coreceptor with CD4 for HIV-1 infection, facilitating viral entry. The interaction with CCL1 highlights its role in mediating cellular responses to this chemokine, implying a regulatory function in immune and inflammatory processes. CCR8 Protein, Human (P. pastoris, His) is the recombinant human-derived CCR8 protein, expressed by P. pastoris, with C-Myc, C-6*His labeled tag. The total length of CCR8 Protein, Human (P. pastoris, His) is 35 a.a., with molecular weight of 7.7 kDa.

HY-P78633

	PD-L1 Protein, Canine (HEK293, His) PD-L1; CD274; B7-H1; PDCD1L1; PDCD1LG1	Canine	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Canine (HEK293, His) is the recombinant canine-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Canine (HEK293, His) is 218 a.a., with molecular weight (glycosylation form) of 50 & 100 kDa, respectively.

HY-P72301

	Protein L1/L1R, Vaccinia virus (Sf9, His, myc) 1 Publications Verification Virion membrane protein M25	Virus	Sf9 insect cells
	Protein L1/L1R is part of the entry fusion complex (EFC) composed of 11 proteins. This complex facilitates the entry of the virion core into the host cytoplasm through a two-step process: lipid mixing of viral and cellular membranes, followed by pore formation. The assembly or stability of the EFC relies on all proteins except OPG095 and OPG053. Protein L1/L1R, Vaccinia virus (Sf9, His, myc) is the recombinant Virus-derived protein L1/L1R, expressed by Sf9 insect cells , with N-His, C-Myc labeled tag. The total length of Protein L1/L1R, Vaccinia virus (Sf9, His, myc) is 182 a.a., with molecular weight of ~27 kDa.

HY-P7231

	LD78-beta/CCL3L1 Protein, Human rHuLD78β/CCL3L1; C-C motif chemokine 3-like 1; SCYA3L1	Human	E. coli
	LD78-beta/CCL3L1 Protein, Human is a potent ligand for the HIV-1 co-receptor CCR5, which is essential for viral entry into human host cells.

HY-P77819

	PD-L1 Protein, Mouse (Biotinylated, HEK293, His) CD274; PDL1; PD-L1; PD-L1B7 homolog 1; B7-H; B7H1; B7-H1; PDCD1L1; PDCD1LG1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Mouse (Biotinylated, HEK293, His) is 220 a.a., with molecular weight of 45-60 kDa.

HY-P78192

	PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) CD274; PDL1; PD-L1; PD-L1B7 homolog 1; B7-H; B7H1; B7-H1; PDCD1L1; PDCD1LG1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) is 220 a.a., with molecular weight of 35-45 kDa.

HY-P76845

	CL-L1/COLEC10 Protein, Mouse (HEK293, Fc) Collectin-10; Collectin liver protein 1; CL-L1	Mouse	HEK293
	CL-L1/COLEC10, operating as a lectin, displays distinct sugar-binding preferences, with a hierarchy of galactose > mannose = fucose > N-acetylglucosamine > N-acetylgalactosamine. Apart from its sugar-binding role, CL-L1/COLEC10 functions as a chemoattractant, suggesting potential engagement in the modulation of cell migration. CL-L1/COLEC10 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CL-L1/COLEC10 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of CL-L1/COLEC10 Protein, Mouse (HEK293, Fc) is 159 a.a., with molecular weight of 53-57 kDa.

HY-P72729

	CD39L1/ENTPD2 Protein, Mouse (HEK293, His) Ectonucleoside triphosphate diphosphohydrolase 2; Entpd2; Cd39L1	Mouse	HEK293
	In the nervous system, CD39L1/ENTPD2 protein crucially regulates purinergic neurotransmission by proficiently hydrolyzing ATP and other nucleotides. Remarkably, it exhibits marginal hydrolysis of ADP, emphasizing its specificity and significant role in precisely modulating purinergic signaling pathways. CD39L1/ENTPD2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD39L1/ENTPD2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD39L1/ENTPD2 Protein, Mouse (HEK293, His) is 437 a.a., with molecular weight of 63-90 kDa.

HY-P72730

	CD39L1/ENTPD2 Protein, Human (HEK293, His) Ectonucleoside triphosphate diphosphohydrolase 2; Entpd2; Cd39L1	Human	HEK293
	CD39L1/ENTPD2 protein, expressed in the nervous system, efficiently hydrolyzes ATP and various nucleotides, while showing limited hydrolysis of ADP. Its substrate specificity hierarchy highlights its regulatory role in purinergic signaling and selective nucleotide hydrolysis, contributing to precise control of neurotransmission. CD39L1/ENTPD2 Protein, Human (HEK293, His) is the recombinant human-derived CD39L1/ENTPD2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD39L1/ENTPD2 Protein, Human (HEK293, His) is 432 a.a., with molecular weight of ~60 kDa.

HY-P76903

	CD39L1/ENTPD2 Protein, Human (sf9, His) Ectonucleoside triphosphate diphosphohydrolase 2; Entpd2; Cd39L1	Human	Sf9 insect cells
	CD39L1/ENTPD2 protein, expressed in the nervous system, efficiently hydrolyzes ATP and various nucleotides, while showing limited hydrolysis of ADP. Its substrate specificity hierarchy highlights its regulatory role in purinergic signaling and selective nucleotide hydrolysis, contributing to precise control of neurotransmission. CD39L1/ENTPD2 Protein, Human (sf9, His) is the recombinant human-derived CD39L1/ENTPD2 protein, expressed by Sf9 insect cells , with N-His labeled tag. The total length of CD39L1/ENTPD2 Protein, Human (sf9, His) is 432 a.a., with molecular weight of ~59 kDa.

HY-P7397

	PD-L1 Protein, Human (CHO, Fc) rHuPD-L1, Fc Chimera; Programmed death ligand 1; CD274; B7-H1	Human	CHO
	PD-L1 Protein, Human (CHO, Fc) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

HY-P7398

	PD-L1 Protein, Human (HEK293, His) rHuPD-L1, His; Programmed death ligand 1; CD274; B7-H1	Human	HEK293
	PD-L1 Protein, Human (HEK293, His) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

HY-P77340

	CL-L1/COLEC10 Protein, Cynomolgus (HEK293, Fc) Collectin-10; Collectin liver protein 1; CL-L1; Collectin-34; CL-34	Cynomolgus	HEK293
	CL-L1/COLEC10, operating as a lectin, displays distinct sugar-binding preferences, with a hierarchy of galactose > mannose = fucose > N-acetylglucosamine > N-acetylgalactosamine. Apart from its sugar-binding role, CL-L1/COLEC10 functions as a chemoattractant, suggesting potential engagement in the modulation of cell migration. CL-L1/COLEC10 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CL-L1/COLEC10 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of CL-L1/COLEC10 Protein, Cynomolgus (HEK293, Fc) is 165 a.a., with molecular weight of ~56.3 kDa.

HY-P70564

	PD-L1 Protein, Cynomolgus (HEK293, His) B7-H; B7H1; B7-H1; PDCD1L1; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293
	CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L1 Protein, Cynomolgus (HEK293, His) is 221 a.a., with molecular weight of 32-40 kDa.

HY-P73361

	PD-L1 Protein, Human (HEK293) 4 Publications Verification Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with tag free. The total length of PD-L1 Protein, Human (HEK293) is 220 a.a., with molecular weight of ~36 kDa.

HY-P73364

	PD-L1 Protein, Rat (HEK293, Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rat	HEK293
	PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Rat (HEK293, Fc) is 221 a.a., with molecular weight of ~63 kDa.

HY-P73365

	PD-L1 Protein, Rat (HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rat	HEK293
	PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, His) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of PD-L1 Protein, Rat (HEK293, His) is 221 a.a., with molecular weight of ~41.79 kDa.

HY-P73717

	PD-L1 Protein, Canine (HEK293, Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Canine	HEK293
	PD-L1 Protein, Canine (HEK293, Fc) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response. The amino acid sequence of PD-L1 is encoded by 7 exons, which form a protein of ~40 kDa. PD-L1 is a type I transmembrane protein, is part of the immunoglobulin (Ig) superfamily and is composed of IgV-like and IgC-like extracellular domains, a hydrophobic transmembrane domain and a short cytoplasmic tail composed of 30 amino acids. PD-L1 can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells. PD-L1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Canine (HEK293, Fc) is 218 a.a., with molecular weight of ~70-80 & 140-160 kDa, respectively.

HY-P71008

	PD-L1 Protein, Cynomolgus (HEK293, Fc) B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293
	CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Cynomolgus (HEK293, Fc) is 221 a.a., with molecular weight of ~73.0 kDa.

HY-P7769

	LD78-beta/CCL3L1 Protein, Human (HEK293 His) rHuCCL3L1, His; C-C Motif Chemokine 3-Like 1; Small-Inducible Cytokine A3-Like 1; Tonsillar Lymphocyte LD78 Beta Protein; CCL3L1; D17S1718; G0S19-2; SCYA3L1; CCL3L3	Human	HEK293
	LD78-beta/CCL3L1 Protein, Human (HEK293 His) is a multiallelic copy number variable, which plays a crucial role in immunoregulatory and hosts defense through the production of macrophage inflammatory protein (MIP)-1α.

HY-P73716

	PD-L1 Protein, Mouse (HEK293, His-Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc, C-His labeled tag. The total length of PD-L1 Protein, Mouse (HEK293, His-Fc) is 238 a.a., with molecular weight of 64-90 kDa.

HY-P70030

	CHI3L1 Protein, Human (HEK293, His) 2 Publications Verification rHuChitinase-3-like protein 1/CHI3L1, His; Chitinase-3-Like protein 1; 39 kDa Synovial Protein; Cartilage Glycoprotein 39; CGP-39; GP-39; hCGP-39; YKL-40; CHI3L1	Human	HEK293
	The CHI3L1 protein is a binding lectin that lacks chitinase activity. CHI3L1 contributes to tissue remodeling, cellular adaptation to environmental changes, and T helper type 2 inflammatory responses. CHI3L1 also controls hyperoxia-induced injury, inflammation, and epithelial cell apoptosis. CHI3L1 Protein, Human (HEK293, His) is the recombinant human-derived CHI3L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CHI3L1 Protein, Human (HEK293, His) is 362 a.a., with molecular weight of 41-48 kDa.

HY-P77347

	PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rhesus Macaque	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is 239 a.a., with molecular weight of ~37.7 kDa.

HY-P70814

	PD-L1 Protein, Rat (221a.a, HEK293, His) B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Rat	HEK293
	PD-L1 Protein is a type I transmembrane protein that belongs to the immunoglobulin (Ig) superfamily. PD-L1 can interact with PD-1, and PD-1/PD-L1 axis is responsible for T cell activation, proliferation, and cytotoxic secretion in cancer, and regulates anti-tumor immune responses. PD-L1 plays a major role in suppressing the adaptive arm of immune systems. PD-L1 Protein, Rat (221a.a, HEK293, His) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L1 Protein, Rat (221a.a, HEK293, His) is 221 a.a., with molecular weight of 40-60 kDa.

HY-P73363

	PD-L1 Protein, Mouse (239a.a, HEK293, Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (239a.a, HEK293, Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Mouse (239a.a, HEK293, Fc) is 239 a.a., with molecular weight of ~51.6 kDa.

HY-P77348

	PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rhesus Macaque	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is the recombinant Rhesus Macaque-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is 239 a.a., with molecular weight of ~26.7 KDa.

Cat. No.	Product Name	Application	Reactivity

HY-P83404

L1CAM Antibody (YA3149)

L1CAM; CAML1; MIC5; Neural cell adhesion molecule L1; N-CAM-L1; NCAM-L1; CD antigen CD171
WB, IHC-P Human
HY-P81625

CD171 Antibody (YA1370)

L1CAM; CAML1; MIC5; Neural cell adhesion molecule L1; N-CAM-L1; NCAM-L1; CD antigen CD171
FC, ELISA Human
HY-P83294

LINE 1 ORF1p Antibody (YA3039)

L1ORF1p; L1RE1; LRE1
WB, IP Human
HY-P81518

LINE-1 ORF1p Antibody (YA1263)

LRE1; L1RE1; LINE-1 retrotransposable element ORF1 protein; L1ORF1p; LINE retrotransposable element 1; LINE1 retrotransposable element 1
IHC-P Human
HY-P83216

GPR182 Antibody (YA2961)

AMR; 7TMR; ADMR; AM-R; G10D; L1-R; gamrh; hrhAMR
WB Human, Mouse, Rat

HY-P80927

VCAM1 Antibody VCAM1; L1CAM; Vascular cell adhesion protein 1; V-CAM 1; VCAM-1; INCAM-100; CD antigen CD106	WB, IHC-P, IP	Human, Mouse, Rat
VCAM1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 81 kDa, targeting to VCAM1. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P82148

ApoL1 Antibody (YA1893)

APOL1; APOL; Apolipoprotein L1; Apolipoprotein L; Apo-L; ApoL; Apolipoprotein L-I; ApoL-I
WB, ICC/IF, IP, FC Human
HY-P82149

S100 alpha9 Antibody (YA1894)

S100 alpha9; Calgranulin-B; Leukocyte L1 complex heavy chain
WB, IHC-F, IHC-P, ICC/IF Mouse
HY-P82036

PUM1 Antibody (YA1781)

HsPUM; PUM L1; Pum1; PUMH 1; PUMH; PUMH1; Pumilio1; PUML1
WB, IHC-F, IHC-P, ICC/IF, IP Human, Mouse

HY-P80273

PD-L1 Antibody	WB, IHC-P	Human
PD-L1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 33 kDa, targeting to PD-L1. It can be used for WB,IHC-P assays with tag free, in the background of Human.

HY-P81513

CD163L1 Antibody (YA1258)

CD163b; CD163L1; CD164L1; M160; Scart1
IHC-P Human
HY-P83318

MAD2L1 Binding Protein Antibody (YA3063)

MAD2L1BP; CMT2; KIAA0110; MAD2L1-binding protein; Caught by MAD2 protein
WB, IHC-P, ICC/IF Human, Mouse, Rat
HY-P81614

BCL2L1 Antibody (YA1359)

BCL2L1; BCL2L; BCLX; Bcl-2-like protein 1; Bcl2-L-1; Apoptosis regulator Bcl-X
FC, ELISA Human
HY-P82948

AK3L1 Antibody (YA2693)

AK3; AK 4; AK3L1; AK3L2
WB, IHC-F, IHC-P, ICC/IF, IP Human
HY-P82704

MAD1L1 Antibody (YA2449)

hMAD1; HsMAD1; MAD1; MAD1L1; PIG9; TP53I9; TXBP181
WB Human, Mouse, Rat
HY-P82442

ATG16L1 Antibody (YA2187)

ATG16L1; APG16L; Autophagy-related protein 16-1; APG16-like 1
WB Human, Mouse, Rat
HY-P81996

Prostaglandin E Synthase Antibody (YA1741)

PGES; MPGES; PIG12; PP102; PP1294; MGST-IV; MGST1L1; TP53I12; mPGES-1; MGST1-L1
WB Human, Mouse, Rat
HY-P82286

ALDH1L1 Antibody (YA2031)

FDH; FTHFD; 10-fTHF; 10-FTHFDH
WB Mouse, Rat
HY-P82747

NAP1L1 Antibody (YA2492)

NRP; NAP1; NAP1L
WB, FC Human, Mouse, Rat

HY-P83228

Wnt2 Antibody (YA2973) Int 1 related protein; INT1L 1; INT1L1; IRP; IRP protein; ONCOGENE INT1 LIKE 1; Protein Wnt-2; Secreted growth factor; Wingless type MMTV integration site family member 2; WNT2	WB	Human, Mouse, Rat

HY-P80655

ENO1 Antibody (YA773) NNE; PPH; MPB1; ENO1L1; HEL-S-17	WB	Human, Mouse, Rat, Monkey
ENO1 Antibody (YA773) is a non-conjugated and Mouse origined monoclonal antibody about 47 kDa, targeting to ENO1 (3F7). It can be used for WB assays with tag free, in the background of Human, Mouse, Rat, Monkey.

HY-P81947

MAD2L1 Antibody (YA1692)

MAD2L1; MAD2; Mitotic spindle assembly checkpoint protein MAD2A; HsMAD2; Mitotic arrest deficient 2-like protein 1; MAD2-like protein 1
WB Human

HY-P83599

MTA2 Antibody (YA3344) Mata1L1; Metastasis associated gene 1 like 1; Metastasis associated gene family member 2; Mmta2; MTA1L1; p53 target protein in deacetylase complex; PID	WB, IHC-P, ICC/IF, FC	Human

HY-P81978

ASH2L Antibody (YA1723)

ASH2; Bre2; ASH2L1; ASH2L2
WB, ICC/IF, IP Human, Rat
HY-P82142

Exocyst Complex Component 3 Antibody (YA1887)

SEC6; Sec6p; SEC6L1
WB, ICC/IF, IP Human, Mouse, Rat
HY-P81868

GNB2 Antibody (YA1613)

Gnb2; Gnb2L1; RACK1; Transducin beta chain 2
WB, IHC-P, IP Human, Mouse, Rat
HY-P81911

Niemann Pick C1 Like 1 Antibody (YA1656)

NPC1 LIKE 1; NPC1L1
WB Human
HY-P82806

SMC3 Antibody (YA2551)

SMC protein 3; Bamacan; SMC3; BAM; BMH; CSPG6; SMC3L1
WB, IHC-P, ICC/IF, FC Human, Mouse, Rat
HY-P82568

KAT2B Antibody (YA2313)

CAF; GCN5; GCN5L; GCN5L1; KAT2B; P/CAF; Pcaf
WB, IP, FC Human, Mouse, Rat
HY-P82163

SCARB1 Antibody (YA1908)

CLA1; SRB1; CLA-1; SR-BI; CD36L1; HDLQTL6; Scavenging Receptor SR-BI
WB, IP Human, Mouse
HY-P82595

SMC4 Antibody (YA2340)

CAPC; hCAP C; hCAP-C; SMC 4; SMC4; SMC4L1; XCAP C homolog
WB, ICC/IF, FC Human, Mouse
HY-P81415

Scavenging Receptor SR-BI Antibody (YA1160)

CLA1; SRB1; CLA-1; SR-BI; CD36L1; HDLQTL6; Scavenging Receptor SR-BI
IHC-P Human
HY-P81407

CDC7 Antibody (YA1152)

CDC7 ; CDC7L1; Cell division cycle 7-related protein kinase; CDC7-related kinase; HsCdc7; huCdc7
IHC-P Human
HY-P83615

mtTFA Antibody (YA3360)

MtTF1; mtTFA; TCF6; TCF6L1; TCF6L2; TCF6L3; TFAM; Transcription factor 6
WB, IHC-F, IHC-P, ICC/IF, IP Human
HY-P83329

NSD3 Antibody (YA3074)

Wolf Hirschhorn syndrome candidate 1 like 1; WHSC1L1; NSD3; pp14328; Histone-lysine N-methyltransferase NSD3; Protein whistle
WB, FC Human, Mouse, Rat
HY-P82273

SMARCB1 Antibody (YA2018)

SMARCB1; BAF47; hSNF5; INI1; RDT; RTPS1; Sfh1p; SMARCB1; SNF5 homolog; SNF5L1; Snr1; SWI/SNF comp
WB, IHC-F, IHC-P, ICC/IF, IP Human, Mouse
HY-P83049

Transcription Factor 7 Like 1 Antibody (YA2794)

Transcription factor 7-like 1; HMG box transcription factor 3; TCF-3; TCF7L1; TCF3
WB, FC Human
HY-P83258

HspA14 Antibody (YA3003)

HSPA14; HSP60; HSP70L1; Heat shock 70 kDa protein 14; HSP70-like protein 1; Heat shock protein HSP60
WB, ICC/IF, IP Human, Mouse

HY-P81303

Phospho-SIRT1 (Ser47) Antibody (YA1036) SIRT1; SIR2L1; NAD-dependent protein deacetylase sirtuin-1; hSIRT1; Regulatory protein SIR2 homolog 1; SIR2-like protein 1; hSIR2	WB, IHC-P, ICC/IF	Human

HY-P81303A

Phospho-SIRT1 (Thr530) Antibody (YA1037)

SIRT1; SIR2L1; NAD-dependent protein deacetylase sirtuin-1; hSIRT1; Regulatory protein SIR2 homolog 1; SIR2-like protein 1; hSIR2
WB Human

HY-P83336

ATG9A Antibody (YA3081) ATG9A; APG9-like 1; Autophagy 9-like 1 protein; Autophagy-related protein 9A; MGD3208; MATG9; APG9 autophagy 9-like 1; APG9L1; Autophagy related 9A	WB, IHC-P, ICC/IF, IP	Human, Mouse, Rat

HY-P81214

MRC1 Antibody Mannose Receptor; C-type lectin domain family 13 member D; CD 206; CD206; CD206 antigen; CLEC13D; CLEC13DL; Macrophage mannose receptor; Mannose receptor C type 1; MMR; MRC 1; MRC-1; MRC1_HUMAN; Macrophage mannose receptor 1; MRC1L1; C-type lectin domain family 13 member D-like; Macrophage mannose receptor 1-like protein 1.	WB; ELISA; Flow-Cyt	Human(predicted: Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Sheep, Guinea Pig)
MRC1 Antibody is an unconjugated, approximately 160 kDa, rabbit-derived, anti-MRC1 polyclonal antibody. MRC1 Antibody can be used for: WB, ELISA, Flow-Cyt expriments in human, and predicted: mouse, rat, chicken, dog, pig, cow, horse, sheep, guinea pig background without labeling.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks